Biotech firm Agenus to begin Phase 1 clinical trial with AGEN1223
Category: #health  By Mateen Dalal  Date: 2020-01-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biotech firm Agenus to begin Phase 1 clinical trial with AGEN1223

Agenus Inc., a U.S. based immuno-oncology firm, has announced that it has started dosing its first patient with AGEN1223, a novel bi-specific antibody developed to reduce regulatory T cells in the tumor microenvironment. The initial dosing was conducted in December 2019 and the study is currently ongoing, with plans to begin combinations with Agenus' investigational PD-1 inhibitor, balstilimab, in 2020.

As per reports, Dr. Anthony El-Khoueiry of the Keck School of Medicine and the USC Norris Comprehensive Cancer Center, is heading the initial dosing program as the clinical investigator. He is the Phase I program director and a renowned expert in translational medicine and early drug development with a focus in pancreatic cancers and hepatobiliary .

According to a statement, Dr. Anna Wijatyk, Head of Clinical Development, Agenus, said that the drug is an exclusive bispecific antibody created to selectively diminish certain immune-suppressive cells termed regulatory T cells. The drug’s ability to deplete such cells in the tumor microenvironment could endow a significant treatment advantage for patients suffering from cancer.

Wijatyk claims that AGEN1223 was formulated to eradicate the escape pathways of tumors, which it commonly uses to resume its growth beyond numerous lines of therapy such as anti-PD-1 therapy. Their firm believes that because of the drug’s design to both activate effector immune cells and selectively reduce intratumoral Tregs while saving peripheral Tregs, AGEN1223 could position itself as a promising combination agent and a crucial novel therapy for patients suffering through aggressive tumors.

In 2019, AGEN1223 had achieved a milestone accomplishment when the biotech’s IND filing for AGEN1223 was accepted by the FDA. The approval strengthens Agenus’s partnership with Gilead Sciences Inc. and initiates a cash payment of $7.5 million.

According to Garo H. Armen, Ph.D., Chairman & CEO, Agenus, this approval comes as the third milestone for the company during its partnership with Gilead.

Source Credit: https://investor.agenusbio.com/2020-01-08-Agenus-Commences-Phase-1-trial-with-AGEN122

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...